Randomized phase II trial of sorafenib, capecitabine and oxaliplatin (SECOX) vs sorafenib in patients with advanced HCC

被引：1
|
作者：
Yau, Thomas [1 ]
Kwok, Gin Wai [1 ]
Tang, Vikki [1 ]
Leung, Roland [1 ]
Lee, Ann-Shing [2 ]
Law, Ada [3 ]
Chiu, Joanne [1 ]
Li, Bryan [1 ]
Cheung, Tan-To [4 ]
机构：
[1] Univ Hong Kong, Dept Med, Hong Kong, Peoples R China
[2] Tuen Mun Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[3] Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[4] Univ Hong Kong, Dept Surg, Hong Kong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz338.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO1 - 5 -
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [1] Randomized phase II trial of sorafenib, capecitabine, and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.
    Kwok, Gin Wai
    Tang, Vikki
    Leung, Roland Ching-Yu
    Lee, Ann-Shing
    Law, Ada
    Chiu, Joanne Wing Yan
    Li, Bryan
    Cheung, Tan To
    Yau, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Randomized phase II trial of sorafenib, capecitabine and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.
    Yau, Thomas Cheung
    Tang, Vikki
    Leung, Roland Ching-Yu
    Kwok, Gin Wai
    Lee, Ann-Shing
    Law, Ada
    Chiu, Joanne
    Li, Bryan
    Cheung, Tan To
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [3] Phase II trial of sorafenib with capecitabine and oxaliplatin (SECOX) in patients with locally advanced or metastatic hepatocellular carcinoma
    Yau, T.
    Chan, P.
    Cheung, F. Y.
    Lee, A. S.
    Yau, T. K.
    Choo, S. P.
    Lau, J.
    Wong, J. S.
    Fan, S. T.
    Poon, R. T.
    EJC SUPPLEMENTS, 2009, 7 (03): : 20 - 21
  • [4] Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)
    Ryoo, B-Y.
    Ren, Z.
    Kim, T-Y.
    Pan, H.
    Rau, K-M.
    Choi, H. J.
    Park, J-W.
    Kim, J. H.
    Yen, C-J.
    Kim, B-H.
    Zhou, D.
    Straub, J.
    Zhao, C.
    Qin, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Phase II study of oxaliplatin high-dose capecitabine and sorafenib in patients with advanced pancreatic cancer
    Lubner, S. J.
    Schelman, W. R.
    Mulkerin, D.
    Holen, K. D.
    Seo, S.
    LoConte, N. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Phase II trial of sorafenib (S) and capecitabine (C) for hepatocellular carcinoma (HCC) in cirrhotic patients (pts).
    Rojas-Hernandez, Cristhiam Mauricio
    Patt, Yehuda Z.
    Fekrazad, M. Houman
    Steinberg, Kim A.
    Roach, Mary
    Lee, Fa-Chyi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] THE USE OF SECOX (SORAFENIB, OXALIPLATIN, CAPCITABINE) AS THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA (HCC) - A SINGLE CENTER RETROSPECTIVE STUDY
    Chiu, J.
    Tang, V.
    Chan, P.
    Leung, R.
    Wong, H.
    Poon, R.
    Fan, S. T.
    Yau, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 244 - 244
  • [8] THE USE OF SECOX (SORAFENIB, OXALIPLATIN, CAPCITABINE) AS THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA (HCC): A SINGLE-CENTER ANALYSIS
    Yau, T.
    Chiu, J.
    Tang, Y. F.
    Chan, P.
    Leung, R.
    Wong, H.
    Fan, S. -T.
    Poon, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 16 - 16
  • [9] Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomised Phase II trial
    Yen, C.
    Kim, T. Y.
    Feng, Y. H.
    Chao, Y.
    Lin, D. Y.
    Studeny, M.
    Hocke, J.
    Huang, D. C. L.
    Ryoo, B. Y.
    Cheng, A. L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S612 - S612
  • [10] Phase II trial of tepotinib vs sorafenib for treatment-naive advanced hepatocellular carcinoma (HCC) in Asian patients
    Ryoo, B-Y.
    Ren, Z.
    Kim, T-Y.
    Pan, H.
    Rau, K-M.
    Choi, H. J.
    Park, J-W.
    Kim, J. H.
    Yen, C-J.
    Kim, B-H.
    Zhou, D.
    Straub, J.
    Zhao, C.
    Qin, S.
    ANNALS OF ONCOLOGY, 2018, 29
12345